+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID06923475

Neoadjuvant Gemcitabine and Cisplatin with Perioperative Pembrolizumab Compared to Upfront Surgery for Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma

Led by Amsterdam UMC, location VUmc · Updated on 2026-08-25

150

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Extrahepatic cholangiocarcinoma eCCA is a rare, aggressive cancer that includes perihilar pCCA and distal cholangiocarcinoma dCCA. Surgical removal is the only potential cure, but only about one-third of patients qualify for surgery. Many experience disease progression before surgery or are found inoperable during exploration. High recurrence and complications limit survival, with low 5-year success rates. This trial studies whether adding neoadjuvant gemcitabine and cisplatin with perioperative pembrolizumab can improve event-free survival in patients with resectable or borderline resectable pCCA and dCCA. Participants are randomly assigned to one of two groups one receiving neoadjuvant gemcitabine and cisplatin combined with perioperative pembrolizumab for up to one year, and the other undergoing upfront surgery as standard care. The neoadjuvant treatment includes two sets of three cycles of chemotherapy combined with immunotherapy. This approach aims to increase complete cancer removal, reduce recurrence, and improve patient selection for surgery. During the study, participants will be monitored regularly for event-free survival at 18 months and overall survival up to five years. Researchers will evaluate outcomes including cancer progression and survival rates. The study involves multiple centers and will follow participants from before treatment through surgery and follow-up, ensuring comprehensive assessment of treatment effects and safety.

CONDITIONS

Brief Title

Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma

Research Team

J

Johanna Wilmink, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here